Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Oyster Point Pharma (NASDAQ:OYST) Issues Quarterly Earnings Results

researchsnappy by researchsnappy
December 29, 2019
in Healthcare Research
0
SalMar ASA (OTCMKTS:SALRF) Rating Increased to Hold at Nordea Equity Research
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Oyster Point Pharma logoOyster Point Pharma (NASDAQ:OYST) issued its quarterly earnings results on Tuesday, December 3rd. The company reported ($8.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($7.59), Fidelity Earnings reports.

Shares of OYST traded down $1.57 during trading hours on Friday, hitting $24.58. The stock had a trading volume of 96,595 shares, compared to its average volume of 123,145. The business’s 50 day moving average is $17.15. Oyster Point Pharma has a 1-year low of $13.26 and a 1-year high of $27.73.

OYST has been the subject of several research reports. Cowen initiated coverage on Oyster Point Pharma in a research note on Monday, November 25th. They issued an “outperform” rating and a $40.00 target price for the company. JPMorgan Chase & Co. initiated coverage on Oyster Point Pharma in a research note on Monday, November 25th. They issued an “overweight” rating and a $26.00 target price for the company. Finally, Piper Jaffray Companies initiated coverage on Oyster Point Pharma in a research note on Monday, November 25th. They issued an “overweight” rating and a $35.00 target price for the company.

In other Oyster Point Pharma news, Director Clare Ozawa purchased 562,500 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The shares were acquired at an average price of $17.02 per share, with a total value of $9,573,750.00. Also, major shareholder Healthcare Strategic Growt Kkr purchased 155,000 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The stock was acquired at an average cost of $17.02 per share, for a total transaction of $2,638,100.00. Over the last 90 days, insiders bought 787,800 shares of company stock valued at $12,438,256.

About Oyster Point Pharma

Oyster Point Pharma, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. It is involved in developing OC-01, a nicotinic acetylcholine receptor agonist that is in Phase IIb clinical trial to treat the signs and symptoms of dry eye disease, as well as Phase III clinical trial for the neurotrophic keratitis.

Recommended Story: Cryptocurrencies



Receive News & Ratings for Oyster Point Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Oyster Point Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Trade99’s ADA Price Analysis: Cardano Manages a Hike of 1.87% Overnight

Next Post

Defense Contractors Paid ‘Protection Money’ To Taliban, Lawsuit Alleges : NPR

Next Post
Defense Contractors Paid ‘Protection Money’ To Taliban, Lawsuit Alleges : NPR

Defense Contractors Paid 'Protection Money' To Taliban, Lawsuit Alleges : NPR

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

Pa. Republicans reconsider Pitt funding over fetal tissue research, college voucher program

Arthur Pharma Closes Series A Financing Round

YouTube and the Achilles Tendon: An Analysis of Internet Information Reliability and Content Quality

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2022 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2022 researchsnappy.com